IBRX - Gunggung utang perusahaan ImmunityBio

ImmunityBio, Inc. (IBRX) is scaling Anktiva sales and penetrating new NK-cell niches. The total liabilities trend visualizes the financial burden, where 0.00 reflects the latest metric value. The operating model relies on full outsourcing of production and testing through external partners, while the R&D center aggressively advances IL-15 research to maximize the company's innovation potential.

NantKwest - Utang perusahaan IBRX (periode 04.07.2022 - 26.10.2026)

Rincian metrik keuangan lan pasar ImmunityBio (IBRX)

- rega lan prakiraan konsensus rega:

Kurs saham NantKwest|IBRX - Prakiraan konsensus analis

- data kapitalisasi pasar:

Biji pasar ImmunityBio Corp|IBRX - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Aset Bersih saben Saham ImmunityBio|IBRX - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku immunitybio.com|IBRX - Aset Agregat Perusahaan

- data utang lan likuiditas:

Utang marang Modal ImmunityBio, Inc.|IBRX - Utang jangka dawa marang modal|Tanggungan utang jangka cendhak marang ekuitas ImmunityBio Inc|IBRX - Gunggung utang perusahaan|Utang-utang marang nilai buku ImmunityBio Corp

Pambiji fundamental perusahaan:IBRX (NantKwest)

Developing innovative vaccines in immuno-oncology requires significant capital, making debt load control critical for the financial stability of ImmunityBio, Inc. (IBRX). This indicator aggregates obligations to creditors and bondholders, eliminating reporting time gaps for accurate solvency monitoring, which allows the investor to assess the balance between business scaling and debt burden via the total debt chart.

Pesaing utama